Diplomat Pharmacy Inc (NYSE:DPLO) – Analysts at William Blair cut their FY2018 earnings estimates for shares of Diplomat Pharmacy in a research report issued on Wednesday, November 7th. William Blair analyst J. Kreger now expects that the company will earn $0.77 per share for the year, down from their previous estimate of $0.82. William Blair also issued estimates for Diplomat Pharmacy’s Q4 2018 earnings at $0.20 EPS, Q1 2019 earnings at $0.23 EPS, Q2 2019 earnings at $0.23 EPS, Q3 2019 earnings at $0.21 EPS, Q4 2019 earnings at $0.23 EPS and FY2019 earnings at $0.91 EPS.
Other equities research analysts also recently issued research reports about the company. ValuEngine raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Tuesday, October 23rd. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co decreased their target price on Diplomat Pharmacy from $23.00 to $16.00 and set a “market perform” rating for the company in a research report on Thursday. Finally, Robert W. Baird downgraded Diplomat Pharmacy from a “neutral” rating to an “underperform” rating and decreased their target price for the stock from $22.00 to $10.00 in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and six have assigned a buy rating to the company’s stock. Diplomat Pharmacy currently has a consensus rating of “Hold” and a consensus target price of $25.20.
Shares of NYSE DPLO opened at $16.05 on Friday. Diplomat Pharmacy has a 1-year low of $13.31 and a 1-year high of $28.74. The company has a quick ratio of 0.63, a current ratio of 0.91 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $1.51 billion, a PE ratio of 19.11 and a beta of 0.95.
Diplomat Pharmacy (NYSE:DPLO) last issued its earnings results on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by ($0.21). Diplomat Pharmacy had a return on equity of 5.33% and a net margin of 0.04%. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.42 billion. During the same period in the previous year, the company earned $0.01 EPS. Diplomat Pharmacy’s quarterly revenue was up 22.0% on a year-over-year basis.
In related news, Director Philip R. Hagerman sold 57,500 shares of the stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total value of $1,104,575.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Philip R. Hagerman sold 209,367 shares of the stock in a transaction dated Thursday, September 13th. The shares were sold at an average price of $19.07, for a total value of $3,992,628.69. The disclosure for this sale can be found here. Corporate insiders own 24.70% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. lifted its holdings in Diplomat Pharmacy by 11.1% during the 2nd quarter. BlackRock Inc. now owns 7,235,761 shares of the company’s stock worth $184,946,000 after buying an additional 724,925 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Diplomat Pharmacy by 9.4% during the 3rd quarter. Janus Henderson Group PLC now owns 5,892,046 shares of the company’s stock worth $114,365,000 after buying an additional 506,878 shares during the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Diplomat Pharmacy by 84.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock worth $68,619,000 after buying an additional 1,614,645 shares during the last quarter. FMR LLC lifted its holdings in Diplomat Pharmacy by 154.4% during the 2nd quarter. FMR LLC now owns 2,798,440 shares of the company’s stock worth $71,528,000 after buying an additional 1,698,341 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in Diplomat Pharmacy by 5.9% during the 2nd quarter. Northern Trust Corp now owns 1,302,681 shares of the company’s stock worth $33,296,000 after buying an additional 72,670 shares during the last quarter. 82.05% of the stock is owned by hedge funds and other institutional investors.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
See Also: How does a reverse stock split work?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.